Latest Conference Coverage


James W. Wheless, MD: The Consequences of Uncontrolled Epilepsy

James W. Wheless, MD: The Consequences of Uncontrolled Epilepsy

July 22nd 2019

The professor and chief of pediatric neurology at Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center spoke about the concerns of uncontrolled epilepsy and how to determine if a patient requires more than one treatment for their epilepsy.


Ubrogepant's Potential in the Migraine Treatment Landscape

Ubrogepant's Potential in the Migraine Treatment Landscape

July 21st 2019

The director of the Headache Center of Southern California shared insight into the success of ubrogepant in patients who failed on triptans, and how the future of migraine treatment may need to focus on combination approaches.


Kelly Knupp, MD: Increasing Patient Curiosity About CBD in Epilepsy

Kelly Knupp, MD: Increasing Patient Curiosity About CBD in Epilepsy

July 19th 2019

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado discussed the popularity of cannabidiol from coverage in the media, and how she sees its use—and the understanding of it—evolving in the coming years.


Researchers Continue to Make In-Roads Towards Infectious Link to Alzheimer Disease

Researchers Continue to Make In-Roads Towards Infectious Link to Alzheimer Disease

July 19th 2019

The topic was the focus of a lively panel discussion and several posters at the 2019 Alzheimer’s Association International Conference, where experts in the field debated on the validity of current findings and theories.


Jonathan Voglein, MD: Epilepsy in Alzheimer Disease

Jonathan Voglein, MD: Epilepsy in Alzheimer Disease

July 19th 2019

This data demonstrates that patients with Alzheimer disease are at an increased risk for seizures, in particular in more advanced disease stages, which emphasizes a need for seizure history assessment to inform individual therapeutic decisions and the necessity of systematic treatment studies.


Blood-Based Biomarkers Promising for Predicting Alzheimer Disease

Blood-Based Biomarkers Promising for Predicting Alzheimer Disease

July 18th 2019

Previous research demonstrated that plasma neuronal-enriched extracellular vesicles exhibited elevated levels of p-tau, amyloid-beta 42, and phosphorylated insulin receptor substrate.


Jessica Ailani, MD: Lowering the Opioid Use Rates in Migraine

Jessica Ailani, MD: Lowering the Opioid Use Rates in Migraine

July 18th 2019

The director of the MedStar Georgetown Headache Center spoke about the higher-than-desired rates of opioid prescriptions for patients with migraine, and how new treatment options and provider education can help lower those numbers.


Improving Alzheimer Care in the Emergency Department: Q&A With Manish Shah, MD, MPH

Improving Alzheimer Care in the Emergency Department: Q&A With Manish Shah, MD, MPH

July 18th 2019

The professor of emergency medicine at the University of Wisconsin-Madison School of Medicine and Public Health spoke about the challenges physicians face in the emergency department when dealing with patients that are cognitively impaired.


Exercise May Protect Against Cognitive Decline in Adults With Elevated Amyloid-Beta

Exercise May Protect Against Cognitive Decline in Adults With Elevated Amyloid-Beta

July 18th 2019

In addition to physical activity, lower vascular risk factors, assessed via the Framingham risk score, were independently associated with slower PACC decline and gray matter volume loss.


Clive Ballard, MD: The State of Nursing Home Care in Dementia

Clive Ballard, MD: The State of Nursing Home Care in Dementia

July 17th 2019

The professor of age-related diseases and Dean of the University of Exeter Medical School spoke about the need for proper training of nursing home staff in order to improve quality of life in patients with dementia.


Susan Hutchinson, MD: The Potential of the Gepant Class in Acute Migraine

Susan Hutchinson, MD: The Potential of the Gepant Class in Acute Migraine

July 17th 2019

The director of the Orange County Migraine and Headache Center spoke about the adherence issues in acute migraine treatment and how the safety profile of investigational medications such as rimegepant and ubrogepant suggests they may be able to address them.


Jeffery Vance, MD, PhD: Role of Genetics in Distinguishing Alzheimer Risk

Jeffery Vance, MD, PhD: Role of Genetics in Distinguishing Alzheimer Risk

July 17th 2019

The professor of neurology and founding chair of the John T. Macdonald Foundation Department of Human Genetics at the University of Miami spoke about how the risk of Alzheimer disease differs between ethnic groups, despite being associated with the same genetic marker.


Using a Precision-Medicine Platform to Address Polypharmacy in Cognitive Impairment

Using a Precision-Medicine Platform to Address Polypharmacy in Cognitive Impairment

July 17th 2019

uMETHOD Health has implemented a precision-medicine platform to create personalized, multidomain care plans for the treatment of dementia and mild Alzheimer disease.


Albumin Replacement Therapy Promising in Mild to Moderate Alzheimer Disease

Albumin Replacement Therapy Promising in Mild to Moderate Alzheimer Disease

July 17th 2019

The AMBAR trial is based off of the hypothesis that amyloid-beta is bound to albumin and circulates in plasma; extracting this plasma may in turn flush amyloid from the brain.


Can Mindfulness-Based Cognitive Therapy Reduce Episodic Migraine Severity and Disability?

Can Mindfulness-Based Cognitive Therapy Reduce Episodic Migraine Severity and Disability?

July 17th 2019

Lead author Elizabeth K. Seng, PhD, shared insight into the findings of an exploration of the use of mindfulness-based cognitive therapy to reduce the impact of migraine on patients, as measured by Migraine Disability Assessment, as well as Headache Disability Inventory scores.


Manish Shah MD, MPH: How Telemedicine Can Reduce ED Use in Dementia

Manish Shah MD, MPH: How Telemedicine Can Reduce ED Use in Dementia

July 16th 2019

The professor of emergency medicine at the University of Wisconsin-Madison School of Medicine and Public Health spoke about how telemedicine in senior living communities can effectively decrease ED use by individuals with dementia.


Cognitive Reserve Linked to Reduced Dementia Risk Regardless of Brain Pathology

Cognitive Reserve Linked to Reduced Dementia Risk Regardless of Brain Pathology

July 16th 2019

The concept of cognitive reserve refers to one’s capacity to be resilient to age-related brain degeneration and disease-related pathology.


Sleep Aid Trazodone May Help Delay Cognitive Decline

Sleep Aid Trazodone May Help Delay Cognitive Decline

July 16th 2019

People who did not use trazodone had up to a 2-fold faster decline in MMSE score than those who used the drug.


Amyloid Accumulation Below Clinical Threshold Still Contributes to Cognitive Decline, Neurodegeneration

Amyloid Accumulation Below Clinical Threshold Still Contributes to Cognitive Decline, Neurodegeneration

July 15th 2019

Findings suggest that a subgroup of patients categorized as amyloid beta-negative may continue to accumulate the destructive protein and experience cognitive changes.


Elzbieta Kuzma, PhD: Healthy Lifestyle Reduces Dementia Risk Despite Genetics

Elzbieta Kuzma, PhD: Healthy Lifestyle Reduces Dementia Risk Despite Genetics

July 15th 2019

The research fellow at the University of Exeter spoke about the findings from her observational study which showed that living a favorable lifestyle could offset the risk for dementia, even if that risk is genetically linked. 




Transcranial Direct Current Stimulation, Working Memory Training Beneficial in Prodromal Alzheimer Disease

Transcranial Direct Current Stimulation, Working Memory Training Beneficial in Prodromal Alzheimer Disease

July 15th 2019

While single modality therapy is safe, feasible, and effective, researchers demonstrated that a combined modality shows greater domain-specific cognitive enhancements with higher transferability and sustainability.


CSF Biomarkers of Neurodegeneration May Predict Progression in Mild Cognitive Impairment

CSF Biomarkers of Neurodegeneration May Predict Progression in Mild Cognitive Impairment

July 14th 2019

Participants with high CSF Aβ1-42/tau and lower NPTX2 levels experienced greater decline throughout the 36 months than all other subgroups on memory acquisition, delayed recall, and CDR-sb.


Adherence May Be Key to VNS Therapy Success in Migraine Prevention

Adherence May Be Key to VNS Therapy Success in Migraine Prevention

July 14th 2019

Investigators found that participants struggled to adhere to the treatment protocol, which required them to administer 3 treatments per day.


Christopher Gottschalk, MD: Advantages of Eptinezumab and CGRP Inhibitors

Christopher Gottschalk, MD: Advantages of Eptinezumab and CGRP Inhibitors

July 14th 2019

The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in migraine treatment, and how eptinezumab fits into the treatment landscape.


Ubrogepant Effective Migraine Treatment Regardless of Prior Triptan Efficacy

Ubrogepant Effective Migraine Treatment Regardless of Prior Triptan Efficacy

July 14th 2019

No differences were observed in the magnitude of ubrogepant treatment effect between defined triptan subgroups.


Dawn Buse, PhD: Where Are Patients With Migraine Seeking Care?

Dawn Buse, PhD: Where Are Patients With Migraine Seeking Care?

July 13th 2019

The clinical professor of neurology at Albert Einstein College of Medicine spoke about the trends revealed by the OVERCOME study, and how this data can be used to improve the management of the millions of patients with migraine in the US.


Richard Lipton, MD: Eptinezumab Maintains Reductions in the Impact of Migraine

Richard Lipton, MD: Eptinezumab Maintains Reductions in the Impact of Migraine

July 13th 2019

The director of the Montefiore Headache Center and professor of neurology at Albert Einstein College of Medicine spoke about the results of an analysis of eptinezumab’s effect on the severity of migraine and its impact on patients’ lives.


Atogepant Effectively Prevents Migraine in Phase 2b/3 Trial

Atogepant Effectively Prevents Migraine in Phase 2b/3 Trial

July 13th 2019

Atogepant significantly reduced mean monthly migraine days compared to placebo across a number of doses and was generally well-tolerated, with no treatment-related serious adverse events.


Real-World Erenumab Data Shows High Use in Chronic Migraine and Persistence to Therapy

Real-World Erenumab Data Shows High Use in Chronic Migraine and Persistence to Therapy

July 13th 2019

Real-world data of erenumab indicates that a large number of patients are the chronic migraine population, and there is a high rate of persistence to the anti-CGRP therapy. The most commonly prescribed dose of erenumab was 70 mg.

© 2025 MJH Life Sciences

All rights reserved.